feed,title,long_url,short_url
Benzinga,Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting,https://benzinga.com/general/biotech/22/11/29825294/arvinass-arv-471-achieves-clinical-benefit-rate-of-38-in-breast-cancer-setting,https://bit.ly/3ABp4Wk
